Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease

Archives of Neurology

Volumn 67, Issue 1, 2010, Pages 99-106

  Wang, Lei ^a   Harms, Michael P ^b   Staggs, Jarrod M ^b   Xiong, Chengjie ^b   Morris, John C ^b   Csernansky, John G ^a   Galvin, James E ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN DISEASE; BRAIN MAPPING; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; FEMALE; HIPPOCAMPAL DEFORMATION; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUBICULUM; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; ATROPHY; BRAIN MAPPING; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NERVE DEGENERATION; PIPERIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 74949092781     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.292     Document Type: Article

References (30)

1. Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351(1):56-67.
2. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211-225.
3. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-397.
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
5. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998;50(3):669-677.
6. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92(26):12260-12264.
7. Jack CR Jr, Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology. 1998;51(4):993-999.
8. Mungas D, Reed BR, Jagust WJ, et al. Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology. 2002;59(6):867-873.
9. Wang L, Swank JS, Glick IE, et al. Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. Neuroimage. 2003;20(2):667-682.
10. Wang L, Miller JP, Gado MH, et al. Abnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type. Neuroimage. 2006;30(1):52-60.
11. Csernansky JG, Wang L, Miller JP, Galvin JE, Morris JC. Neuroanatomical predictors of response to donepezil therapy in patients with dementia. Arch Neurol. 2005;62(11):1718-1722.
12. Jack CR Jr, Petersen RC, Grundman M, et al; Members of the Alzheimer's Disease Cooperative Study (ADCS). Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008;29(9):1285-1295.
13. Modrego PJ. The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques. Curr Med Chem. 2006;13(28):3417-3424.
14. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
15. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55(3):326-335.
16. Morris JC, Ernesto C, Schafer K, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology. 1997;48(6):1508-1510.
17. Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002;59(7):1034-1041.
18. Kanne SM, Balota DA, Storandt M, McKeel DW Jr, Morris JC. Relating anatomy to function in Alzheimer's disease: neuropsychological profiles predict regional neuropathology 5 years later. Neurology. 1998;50(4):979-985.
19. Rubin EH, Storandt M, Miller JP, et al. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol. 1998;55(3):395-401.
20. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983;140(6):734-739.
21. Wechsler D. Wechsler Memory Scale. 3rd ed. San Antonio, TX: The Psychological Corp; 1997.
22. Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23(2):724-738.
23. Csernansky JG, Wang L, Joshi SC, Ratnanather JT, Miller MI. Computational anatomy and neuropsychiatric disease: probabilistic assessment of variation and statistical inference of group difference, hemispheric asymmetry, and time-dependent change. Neuroimage. 2004;23(suppl 1):S56-S68.
24. Freeborough PA, Woods RP, Fox NC. Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders. J Comput Assist Tomogr. 1996;20(6):1012-1022.
25. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709-7717.
26. Csernansky JG, Wang L, Swank J, et al. Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage. 2005;25(3):783-792.
27. SAS System for Windows [computer program]. Version 9.1.3. Cary, NC: SAS Institute Inc; 2004.
28. Fleisher AS, Sun S, Taylor C, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008;70(3):191-199.
29. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry. 2005;162(4):676-682.
30. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003;160(11):2003-2011.